Nuvectis Pharma, Inc.NASDAQ: NVCT

Nuvectis Pharma Announces Participation at Upcoming Investor Conferences

· Issued by Nuvectis Pharma, Inc. via GlobeNewswire

Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced that Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis, will present at the following investor conferences:

EventOppenheimer 34th Annual Healthcare Life Sciences Conference
DateFebruary 13, 2024
Time10:00 AM ET
LocationVirtual
Webcast Linkhttps://wsw.com/webcast/oppenheimer33/nvct/2804822
Event2024 NeauxCancer Oncology Conference
DateMarch 1, 2024
Time1:00 PM CST
LocationNew Orleans, LA

About Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology. The Company is currently developing two drug candidates, NXP800 and NXP900. NXP800 is an oral small molecule currently in a Phase 1b clinical trial investigating the activity of NXP800 as a potential treatment for platinum resistant, ARID1a-mutated ovarian carcinoma. The U.S. Food and Drug Administration (“FDA”) granted Fast Track Designation to the NXP800 development program in platinum resistant, ARID1a-mutated ovarian carcinoma, and Orphan Drug Designation for the treatment of cholangiocarcinoma. NXP900 is a novel, small molecule SRC/YES1 kinase inhibitor. The NXP900 Investigational New Drug Application has been cleared by the FDA and a Phase 1a dose escalation study is expected to begin in Q3 2023.

Company Contact

Ron Bentsur Chairman, Chief Executive Officer and President 201-614-3151 [email protected]

Media Relations Contact

Christopher M. Calabrese LifeSci Advisors Tel: 917-680-5608 [email protected]

Primary Logo

Source: Nuvectis Pharma, Inc.

Nuvectis Pharma, Inc. on 6ix

Earlier from Nuvectis Pharma

Later from Nuvectis Pharma

All Nuvectis Pharma news releases